Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2023 Filed Nov 21, 2023 02:14 UTC Amendment |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 55,468 | $148.90 Strike: $148.90 | $8,259,185.20 |
DisclosureSEC source: 0001127602-23-028095 · form4a.xml · derivative · entry 6 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,468 Underlying: ResMed Common Stock · 55,468 shares Expires 2030-11-16 F5 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 02:14 UTC Amendment |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,462 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-028095 · form4a.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 3,462 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Transaction was a plan auto exercise prior to expiration. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 02:14 UTC Amendment |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 1,343 | $148.90 | $199,972.70 |
DisclosureSEC source: 0001127602-23-028095 · form4a.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,105 F2 · kind: Disposition to issuer for exercise cost of options auto-exercised under the plan. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 02:14 UTC Amendment |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 3,462 | $57.76 | $199,965.12 |
DisclosureSEC source: 0001127602-23-028095 · form4a.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Original form amended to include a plan provision auto-exercise prior to option grant expiration. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:28 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028092 · form4.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,713 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:25 UTC |
De Witte JanDirector
|
GrantReMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028090 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,879 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:21 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028086 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,955 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2024, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:22 UTC |
Hernandez JohnDirector
|
GrantResMed Common Stock Options · Derivative | 2,575 | $148.90 Strike: $148.90 | $383,417.50 |
DisclosureSEC source: 0001127602-23-028088 · form4.xml · derivative · entry 2 Hernandez John · CIK 0001890555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575 Underlying: ResMed Common Stock · 2,575 shares Expires 2030-11-16 F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:22 UTC |
Hernandez JohnDirector
|
GrantResMed Common Stock | 884 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028088 · form4.xml · nonDerivative · entry 1 Hernandez John · CIK 0001890555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,962 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2024, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 23:53 UTC |
Tan DesneyDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028048 · form4.xml · nonDerivative · entry 1 Tan Desney · CIK 0001890548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,846 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2024, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 00:01 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028057 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,846 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 23:45 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028038 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,615 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 23:50 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028045 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,939 F1 · shares: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2024, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:46 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 55,468 | $148.90 Strike: $148.90 | $8,259,185.20 |
DisclosureSEC source: 0001127602-23-028004 · form4.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,468 Underlying: ResMed Common Stock · 55,468 shares Expires 2030-11-16 F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:47 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock Options · Derivative | 2,575 | $148.90 Strike: $148.90 | $383,417.50 |
DisclosureSEC source: 0001127602-23-028005 · form4.xml · derivative · entry 2 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575 Underlying: ResMed Common Stock · 2,575 shares Expires 2030-11-16 F2 · derivative.exercise_date: Represents the date options become exercisable. Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:47 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 884 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028005 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,871 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2024, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 21:36 UTC Amendment |
Burt CarolDirector
|
GrantResMed Common Stock | 1,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-028141 · form4a.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,890 F1 · balance_after: Amended to reflect change in holdings between direct and indirect for shares transferred. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 02:20 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,678 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-027688 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,462 Underlying: ResMed Common Stock · 5,678 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 02:20 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,678 | $152.04 | $863,280.85 |
DisclosureSEC source: 0001127602-23-027688 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,986 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.92 to 153.51. The price reported above reflects the weighted average sale price. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 02:20 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,678 | $57.76 | $327,961.28 |
DisclosureSEC source: 0001127602-23-027688 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 446,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:34 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 93.367 | $143.60 | $13,407.50 |
DisclosureSEC source: 0001127602-23-027469 · form4.xml · nonDerivative · entry 4 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,960 F4 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020. F5 · balance_after: Includes 41.402 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:34 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 136.592 | $143.60 | $19,614.61 |
DisclosureSEC source: 0001127602-23-027469 · form4.xml · nonDerivative · entry 3 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,054 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:34 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 117.573 | $143.60 | $16,883.48 |
DisclosureSEC source: 0001127602-23-027469 · form4.xml · nonDerivative · entry 2 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,190 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:34 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 91.637 | $143.60 | $13,159.07 |
DisclosureSEC source: 0001127602-23-027469 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,308 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:28 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 435.943 | $143.60 | $62,601.41 |
DisclosureSEC source: 0001127602-23-027467 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,275 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F3 · balance_after: Includes 28.354 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:28 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 590.733 | $143.60 | $84,829.26 |
DisclosureSEC source: 0001127602-23-027467 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,711 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:23 UTC |
Douglas Robert AndrewPresident and COO
|
Tax withholdingResMed Common Stock | 759.74 | $143.60 | $109,098.66 |
DisclosureSEC source: 0001127602-23-027465 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,224 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. F3 · balance_after: Includes 54.45 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:23 UTC |
Douglas Robert AndrewPresident and COO
|
Tax withholdingResMed Common Stock | 944.542 | $143.60 | $135,636.23 |
DisclosureSEC source: 0001127602-23-027465 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,985 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:07 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 2,181.29 | $143.60 | $313,233.24 |
DisclosureSEC source: 0001127602-23-027463 · form4.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,986 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F4 · balance_after: Includes 78.152 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:07 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,037.906 | $143.60 | $436,243.30 |
DisclosureSEC source: 0001127602-23-027463 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,167 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 01:07 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,232.71 | $143.60 | $464,217.16 |
DisclosureSEC source: 0001127602-23-027463 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,205 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 00:33 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
Tax withholdingResMed Common Stock | 135.354 | $143.60 | $19,436.83 |
DisclosureSEC source: 0001127602-23-027461 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,305 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. F2 · balance_after: Includes 85.032 shares of ResMed stock purchased on October 31, 2023, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 00:00 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 325.375 | $143.60 | $46,723.85 |
DisclosureSEC source: 0001127602-23-027459 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,171 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 23:11 UTC |
Gill HarjitDirector
|
Tax withholdingResMed Common Stock | 79.202 | $143.60 | $11,373.41 |
DisclosureSEC source: 0001127602-23-027452 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,187 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 01:29 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 25 | $143.42 | $3,585.50 |
DisclosureSEC source: 0001127602-23-026700 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,358 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 24, 2023. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 22:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-026027 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,140 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options are exercisable 1/3 each year beginning 1 year from date of grant. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 22:50 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $140.70 | $798,463.99 |
DisclosureSEC source: 0001127602-23-026027 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 449,360 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $139.745 to 141.56. The price reported above reflects the weighted average sale price. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 22:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-026027 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 14:57 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 25 | $145.92 | $3,648.00 |
DisclosureSEC source: 0001127602-23-025408 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,383 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 24, 2023. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 18:54 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-23-024408 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,815 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F3 · derivative.exercise_date: Options are exercisable 1/3 each year beginning 1 year from date of grant. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 18:54 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $146.35 | $830,513.55 |
DisclosureSEC source: 0001127602-23-024408 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 449,360 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $145.09 to 148.07. The price reported above reflects the weighted average sale price. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 18:54 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-23-024408 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 19:44 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 25 | $161.15 | $4,028.75 |
DisclosureSEC source: 0001127602-23-023838 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,408 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 24, 2023. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 21:56 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
Tax withholdingResMed Common Stock | 379.689 | $165.67 | $62,903.08 |
DisclosureSEC source: 0001127602-23-023392 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,355 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 07/01/2022. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:09 UTC |
Rider Michael JGlobal General Counsel
|
GrantResMed Common Stock | 2,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022933 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,433 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:08 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
GrantResMed Common Stock | 3,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022931 · form4.xml · nonDerivative · entry 2 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,735 F2 · kind: Represents performance-based restricted stock units granted on July 1, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:08 UTC |
BLAISE LUCILEPresident, Sleep & RC Business
|
GrantResMed Common Stock | 819 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022931 · form4.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,441 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:06 UTC |
Ghoshal KaushikPresident, SaaS Business
|
GrantResMed Common Stock | 2,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022929 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,273 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:03 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 4,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022927 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,915 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 17:02 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 12,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022925 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,360 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on August 17, 2023, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.